SML3621

Erlotinib

Name: Erlotinib
Brand: SIGMA

≥98% (HPLC), EGFR tyrosine kinase inhibitor, powder

Synonym(s):

4-[(3-Ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline, 6,7-Bis(2-methoxy-ethoxy)-quinazolin-4-yl]- (3-ethynyl-phenyl)amine, Erlotinib free base, N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine, NSC 718781, OSI-774

Select a Size

All Photos(1)

About This Item

Empirical Formula (Hill Notation):

C₂₂H₂₃N₃O₄

CAS Number:

183321-74-6

Molecular Weight:

393.44

UNSPSC Code:

12352200

NACRES:

NA.77

MDL number:

MFCD02089651

Product Name

Erlotinib, ≥98% (HPLC)

SMILES string

N(c3cc(ccc3)C#C)c1ncnc2c1cc(c(c2)OCCOC)OCCOC

InChI key

AAKJLRGGTJKAMG-UHFFFAOYSA-N

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

-10 to -25°C

Quality Level

100

Related Categories

Bioactive Small Molecule Inhibitors

Bioactive Small Molecules

Biochem/physiol Actions

Erlotinib is an orally available, potent, and specific inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase. Erlotinib binds to the ATP binding site of the receptor. It is used to treat lung and pancreatic cancer.

orally available, potent, and specific inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase

pictograms

GHS07

signalword

Warning

hcodes

H302

pcodes

P264 - P270 - P301 + P312 - P501

Hazard Classifications

Acute Tox. 4 Oral

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor.

Jennifer Stamos et al.

The Journal of biological chemistry, 277(48), 46265-46272 (2002-08-28)

The crystal structure of the kinase domain from the epidermal growth factor receptor (EGFRK) including forty amino acids from the carboxyl-terminal tail has been determined to 2.6-A resolution, both with and without an EGFRK-specific inhibitor currently in Phase III clinical

EGFR inhibition reverses resistance to lenvatinib in hepatocellular carcinoma cells.

Xiaoping He et al.

Scientific reports, 12(1), 8007-8007 (2022-05-15)

Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death worldwide. Lenvatinib is approved as a first-line treatment for unresectable HCC. The therapeutic duration of lenvatinib is limited by resistance, but the underlying mechanism is unclear. To establish lenvatinib-resistant cells

Mediating EGFR-TKI Resistance by VEGF/VEGFR Autocrine Pathway in Non-Small Cell Lung Cancer.

Chike Osude et al.

Cells, 11(10) (2022-05-29)

NSCLC treatment includes targeting of EGFR with tyrosine kinase inhibitors (TKIs) such as Erlotinib; however, resistance to TKIs is commonly acquired through T790M EGFR mutations or overexpression of vascular endothelial growth factor receptor-2 (VEGFR-2). We investigated the mechanisms of EGFR-TKI

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service